Recombinetics is a recognized leader in the development and deployment of gene-editing technologies to advance human health and the welfare and productivity of food animals.
Founded in 2008, Recombinetics is a privately held Minnesota-based biotechnology company that aims at helping to solve some of the world’s most intractable challenges. Through gene editing, Recombinetics can have a transformative impact on humanity from improving health outcomes to feeding growing populations. Recombinetics is delivering viable products and generating revenues today from the large and growing biomedical and agricultural markets.
RCI focused its early stage development on the application of precision genetic technologies and active patent filings in animals. Development of advanced “gene-editing” technologies for commercial purposes began in 2011. Today, RCI is widely recognized as the leader in livestock gene-editing and associated applied technologies for biomedical research, regenerative medicine, and animal agriculture.
RCI’s first gene-edited animals are generating revenues today with a pipeline of animals under development for the large biomedical and agricultural markets.
RCI is a company built on firsts.
With a robust intellectual property portfolio, RCI leverages its research platform to commercialize and deploy its invented and licensed technologies across key markets.
RCI’s growing global patent portfolio includes 18 issued patents, more than 200 additional applications filed, and first use and enabling patents for livestock for both CRISPR and TALENs. Here are some of RCI’s achievements in science.
- Some key business highlights include:
- The world’s first sale of gene-edited pig models to a globally-recognized medical clinic for use in human cardiac therapeutic applications;
- Global rights for TALENs as a principal tool for gene-editing in large animals to facilitate human biomedical research, regenerative medicine, and enhanced animal welfare and food production;
- Global reach and presence, with local leadership across Asia/Pacific and South America and significant patent issuance across Australia, New Zealand, China and elsewhere;
- First enabled livestock animal patent filing using CRISPR/Cas9; and
- Substantial intellectual property in advanced reproductive physiology.